Galvani Bioelectronics Secures £5.3m to Advance Bioelectronic Medicines

Galvani Bioelectronics Limited, a Stevenage-based medical research company dedicated to developing bioelectronic medicines, has successfully raised £5.3 million in its latest funding round. The allotment for this capital injection was made on 2026-04-15, with the filing date recorded as 2026-04-27. This funding is set to bolster the company's efforts in pioneering implant-based therapies designed to modulate specific neural signals to treat chronic diseases.

Founded on 2016-02-03, Galvani Bioelectronics addresses the significant challenge of chronic diseases by developing innovative treatments for conditions such as rheumatoid arthritis, bladder dysfunction, and hypertension. Their approach focuses on restoring health in patients through targeted neuromodulation. The company operates as a joint venture between pharmaceutical giant GSK and Verily Life Sciences, a subsidiary of Alphabet Inc., providing a strong foundation of expertise and resources in both medical research and advanced technology.

According to its latest available accounts, Galvani Bioelectronics reported a profit/loss of £-15,917,000, reflecting the substantial investment typically required for deep tech medical research and development. The company's employee count stands at 22 based on these accounts, while its LinkedIn profile indicates a slightly higher figure of 33 employees, highlighting its growth in the specialised field of medical equipment manufacturing.

This recent £5.3 million funding round marks another significant step in Galvani Bioelectronics' financial journey. The company has a history of attracting substantial investment, with previous notable rounds including £7.5 million on 2021-03-29 and £6.2 million on 2020-06-03. More recently, in 2024, the company secured several smaller tranches of funding, including £2.3 million and £342.2k on 2024-05-10, and £34k on 2024-09-30. This latest £5.3 million round demonstrates continued investor confidence in Galvani Bioelectronics' long-term vision and its potential to deliver transformative medical solutions.

The funding landscape for UK biotech and health tech companies has shown signs of recovery in early 2026, providing a supportive environment for companies like Galvani Bioelectronics. In the first quarter of 2026, total equity financing for the UK biotech sector reached £552 million, an increase from £466 million in Q4 2025. Venture capital was a primary driver, rising 17% quarter-on-quarter to £516 million from £442 million. This period was characterised by a broader distribution of investment across more companies and stages, with deal activity increasing significantly to 25 VC transactions, a 67% year-on-year rise. Notably, the UK secured 57% of all European biotech venture capital in Q1 2026, underscoring its leading position in the continent's biotech market.

While 2025 was a challenging year for the UK biotech sector, with venture capital investment decreasing by 13.2% year-on-year to £1.8 billion, deal activity did accelerate towards the end of the year. The health tech sector, in particular, has demonstrated significant value, with UK health tech startups valued at £32 billion at the end of 2024. In Q1 2025, health tech and life sciences startups collectively raised approximately £1.33 billion (US$1.8 billion), making health the most funded sector in the UK during that quarter.

Galvani Bioelectronics operates within the burgeoning neuromodulation devices market. The UK neuromodulation devices market generated £181.5 million in revenue in 2023 and is projected to reach £445.3 million by 2030, exhibiting a compound annual growth rate of 13.7% from 2024 to 2030. Internal neuromodulation technologies, which are central to Galvani Bioelectronics' work, held the largest market share in 2024. The UK government has also expressed a vision to become a leader in neurotechnology, with initiatives focused on advancing neuromodulation. However, challenges remain, such as the current lack of NHS funding for some advanced neurotechnologies, which can impact market growth.

This latest funding round positions Galvani Bioelectronics to continue its vital research and development in bioelectronic medicines, contributing to the UK's strong and recovering health tech and biotech sectors. The company's focus on innovative, implant-based therapies aligns with the growing neuromodulation market and the broader strategic importance of neurotechnology in addressing chronic diseases.